The agreement was signed in August 2010 for the development and commercialization of injectable drug candidate, ATX-101, outside the US and Canada.
Kythera also received €14.1m ($17.5m) to fund certain further global development activities of ATX-101 under the terms of the collaboration arrangement.
Bayer’s decision to pursue continued development and regulatory approvals for ATX-101 after receiving positive results from pivotal European Phase III clinical trials triggered the payments.
The proprietary formulation of synthetic sodium deoxycholate is a well-characterized component of human bile that is naturally occurring in the body and promotes the breakdown of dietary fat.
ATX-101 is designed to be a locally-injected drug that causes proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue.